Dear colleagues,
We had a successful spring with strong results in all four segments. Well done everyone!
We are growing above the average animal health market, our customers appreciate the quality of our products and services, and we continue to attract new companies and entrepreneurs that are keen to join our family. Dialogues with new companies have intensified in the past months and the team is now working hard to push these conversations over the finish line.
During May and June, we completed our annual business planning process where we look five years ahead and set the direction for our development. I was excited to see all the innovations and initiatives across each segment. We also discussed how we can strengthen the Group’s support to our segments and businesses by leveraging new technology and how to continue investing in our culture. Our overall strategy, to build a global leader in select niches of animal health with clear unmet medical needs, remains.
Thank you for a very strong quarter and first half of the year and I hope you will enjoy some relaxing summer holidays together with your two-legged and four-legged family members and friends!
We're excited to launch Vimian Connect, our new hub available to all employees globally. The portal offers a searchable employee directory, ethics training, an AI activation hub with use cases, a policy library with a Q&A chatbot, and more. How do you get in? Go to connect.vimian.com, enter your work email address, and you'll receive a magic link. Just click it and you're in. No passwords, no extra accounts.
At launch, Vimian Connect includes:
VetFamily has recently expanded into three new geographies, Portugal, Ireland, and Japan. We sat down with Linn Hultberg, Business Development Director at VetFamily, to learn about the approach to new market entries.
Growing a business across borders requires a structured approach. When evaluating a new market, Linn explains, the team analyses a consistent set of factors, e.g.: the number and size of clinics, the share owned by corporate chains versus independent operators, spending per pet, and whether pharmaceutical products are sold through the clinic or via pharmacies.
Japan is one of the world's largest economies, has some 16 million dogs and cats, and approximately 12,000 veterinary clinics, of which only a small proportion are corporate-owned. Japanese pet owners spend around €1,200 per dog per year, and pharmaceutical sales predominantly flow through clinics rather than pharmacies. Factors that are highly attractive for VetFamily's membership model and sparked an interest to take a closer look at the market.
With urban living spaces that are famously compact and birth rates that continue to fall, pets, particularly cats and small dogs, have become central to many households.
Equally important was finding the right person on the ground. Through its longstanding relationship with Boehringer Ingelheim, VetFamily connected with Hiro, the outgoing head of the company's Japanese animal health division, who spent 18 months mapping the market, conducting 120 clinic interviews, and laying the groundwork for launch. The results were encouraging: clinics rated the VetFamily proposition 4.2 out of 5 for likelihood to join.
As of 1 April 2026, Keiichiro (Kei) Yoshimoto has joined as Country Manager, while Hiro remains part of the team in a role as senior consultant.
“When I first encountered the VetFamily model, I immediately saw its potential here. Japanese pet owners are deeply committed to their animals' wellbeing, and yet the market remains largely fragmented and independent. Exactly the kind of environment where VetFamily can make a difference.” - Keiichiro Yoshimoto, Country Manager, VetFamily Japan.
VetFamily is formally launching its business in Japan this month, with procurement and community services forming the initial offering. Partner agreements with manufacturers and wholesalers are being finalised, and clinic recruitment now begins in earnest.
Nextmune is proud to introduce the next generation of PAX, the world's most advanced veterinary allergy test. Developed in Q4 2025 and launching soon, this updated version includes 25 allergens newly identified as relevant for dogs, through a collaboration with a leading American immunology biotech company.
Nextmune designed a new version of the allergy test PAX in Q4 2025, which will launch soon. This new version includes 25 additional allergens newly identified as relevant for dogs through a collaboration with an American immunology biotech company.
PAX is today the most advanced veterinary allergy test worldwide, and, like many human allergy tests, it focuses on the most allergenic proteins in extracts, in contrast to extract-based skin or serum tests still used by most practitioners.
“This second PAX version does a better job of identifying which specific allergens each pet reacts to. This makes it possible to customise allergy treatments more precisely for each pet, which should lead to better results and a competitive edge in the market." - Prof. Thierry Olivry, DrVet, PhD, Head of R&D, Nextmune AB, Stockholm
Most "I keep hitting usage limits" frustration traces back to a few habits where the fix is simple. These 6 easy steps can help you!
These take minutes to adopt. 👉 Full guidance on the new AI Activation guide on Vimian Connect.
Check out this video from Movora where a dog gets new mobility after treatment with OrthoSta, a streamlined stabilisation system designed to support confident recovery from cruciate ligament injuries. Now, this little champion is ready for new adventures! Link here.
At the end of August, leaders from across Vimian will gather in France for the first-ever Global Leadership Conference, an important investment in building a stronger, more connected Vimian.
Over three days, leaders from different segments, functions, and countries will align on strategy and priorities, share best practices, and explore opportunities to create value together.
By strengthening relationships across the group and developing a shared understanding of where we are heading, participants will return with new ideas, insights, and connections that can benefit their teams and everyday work.
As Vimian continues to grow, bringing leaders and key contributors together is an important step in ensuring that we combine the strength of our individual businesses with the power of one global organisation. The conversations start in France, but the impact should be felt across the entire group.
Did you know that there are 22 dog breeds that should not appear in Vimian's marketing and communications (unless used for clinical purposes)? The images we publish shape what people see as normal, healthy and desirable, so every animal we show should be one living the best life possible. Our new Animal Welfare Image Assessment Tool makes that simple.
Built on our updated guidelines and the Five Welfare Needs, it checks any image in seconds, flagging extreme conformations, mutilations, aversive devices and tense body language before they reach print. Check before you publish 👉 https://connect.vimian.com/animal-welfare